Background: Although usually a problem of cisplatin-based chemotherapy, delayed emesis can cause severe distress in patients treated with cyclophosphamide. Dexamethasone has been shown to be effective in the control of cisplatin-induced delayed emesis, but its role against the delayed problem in patients treated with cyclophosphamide has not been demonstrated. Our study was conducted to evaluate the effect of dexamethasone in delayed emesis induced by cyclophosphamide.
Introduction
The development of the 5-HT3 receptor antagonist has been one of the most significant recent advances in chemotherapy of cancer patients. Effective control of treatment-induced vomiting results in better quality of life for patients [1, 2] , and improves compliance with chemotherapy schedules [3] . 5-HT3 receptor antagonists have been shown to be superior to conventional antiemetics in the control of acute vomiting induced by moderately emetogenic chemotherapy [4, 5] , and at least as effective in highly emetogenic chemotherapy such as cisplatin-containing regimens [6] .
While being effective in acute emesis, 5-HT3 receptor antagonists fail to protect against delayed emesis, defined as nausea and vomiting occurring 24 hours after chemotherapy. This is particularly common after high-dose cisplatin, and may occur in the absence of acute emesis. The pathophysiology is poorly understood, but the severity is well recognised and affected patients often need to be hospitalised [7, 8] . Dexamethasone, orally or parenterally, was able to potentiate antiemetic activity of 5-HT3 antagonists [9] , and has also been shown to control delayed emesis in patients treated with cisplatin [10] .
We studied the efficacy of maintenance oral dexamethasone following i.v. granisetron plus i.v. dexamethasone, and compared it with single-dose i.v. granisetron and dexamethasone without oral maintenance. Granisetron is a 5-HT3 receptor antagonist with proven efficacy in the control of acute emesis [11, 12] . The present study was undertaken to determine the effectiveness of maintainance oral dexamethasone in preventing delayed emesis induced by non-cisplatin chemotherapy.
Patients and methods
Ninety-eight chemo-naive patients participated in the study. Patients were considered eligible if they fulfilled the following criteria; histologically-proven malignant disease and no previous cytotoxic chemotherapy, aged 16 and above, performance status WHO 0, 1 or 2, able to understand and sign consent for clinical trial. Exclusion criteria included liver function test abnormality defined as transaminases more than 4 times the upper limit, abnormal renal function as defined by a creatinine level more than double the upper limit, vomiting within the past week, radiologically-proven symptomatic primary or secondary brain tumour, active peptic ulcer disease, gastric compression or tumour involvement of gastrointestinal tract likely to cause intestinal obstruction, and other active medical conditions such as congestive cardiac failure, diabetes mellitus, partial or generalised seizure during the past year. Patients receiving concurrent radiotherapy and drug treatment such as corticosteroids, benzodiazepines and other tranquilisers were excluded.
A profile of the patients is listed in Table 1 . All of them received their cytotoxic chemotherapy on the first day. Chemotherapy regimens included bolus cyclophosphamide more than 750 mg/m 2 , or cyclophosphamide more than 500 mg/m 2 if given concurrently with other emetogenic cytotoxics.
The eligible patients were then randomised to receive either i.v. granisetron 3 mg plus i.v. dexamethasone 8 mg, followed by oral dexamethasone 4 mg twice daily on days 2 to 5 for four days (regime GIO), or i.v. granisetron 3 mg plus i.v. dexamethasone 8 mg without n further maintenance dexamethasone (regimen GDI). Granisetron was diluted in 20 ml of sterile normal saline and given by slow i.v. infusion over 5 minutes, to be completed 10 minutes before cytotoxic chemotherapy. Dexamethasone was diluted in 20 ml normal saline and infused over 5 minutes, to be completed 5 minutes prior to granisetron infusion. Efficacy of antiemeu'c therapy was determined by patients' subjective assessment of nausea control, and episodes of vomiting. Complete responders were patients who had no vomiting episode, no or mild nausea, and did not require rescue therapy during the assessment period. Major responders were patients who had only one episode of vomiting, or no vomiting but a moderate to severe degree of nausea after chemotherapy. Minor responders had two to four episodes of vomiting regardless of nausea rating. Failure refers to patients who vomited more than four times regardless of their nausea rating.
The chi-square test was used to assess the difference between the two groups of patients, the p value of < 0.05 was regarded as significant.
Results
During the period from 31 July 1993 to 16 September 1994, a total of 98 patients who fulfilled entry criteria agreed to participate in the trial. They were randomised to the two treatment arms. Ninety-four patients completed the self-assessment clinical report form, 46 received maintainance oral dexamethasone (GIO), and 48 did not (GDI). Their profile is shown in Table 1 .
On the first day of chemotherapy, of the 46 who were given i.v. granisetron and dexamethasone, followed by oral dexamethasone, i.e., regimen GIO, 36 (78%) were complete responders, and 9 (18%) were major responders. They was no failure of emesis control. For patients who were given regimen GDI, i.e., those who would not receive maintenance dexamethasone later, 33 (69%) were complete responders and 7 (15%) were major responders. Two patients (4%) vomited on more than 4 occasions and were considered failures. There was no significant difference in terms of complete response between the two groups of patients, and the overall complete response for the study population as a whole was 73%. Eighty-five patients (90%) had no vomiting or only one episode with mild nausea.
During the subsequent self-assessed period of days 2 to 7, 26 (57%) who were given oral dexamethasone (GIO) were complete responders and 14 (30%) were major responders. One patient (2%) had more than 4 episodes of vomiting despite oral dexamethasone. Of the other 48 patients who were not given oral dexamethasone, i.e., the GDI regimen, 16 (33%) were complete responders and 7 (15%) were major responders. Eleven (23%) failures vomited on more than 4 occasions. Most of the emetic episodes occurred within the first 4 days of treatment ( Figs. 1 and 2 ). During the entire 7-day study period, 87% of patients given oral dexamethsone (GIO) had no vomiting or only one episode with mild nausea, compared to 48% of patients without maintenance oral dexamethasone (Fig. 3) . The difference is statistically significant (p < 0.001).
Of the two patients in the GDI group who had more than 4 episodes of vomiting during the first 24 hours, one achieved a minor response over the next few days, and the other vomited 7 times the next day. Acute emesis during the first day of chemotherapy is a known risk factor for subsequent development of delayed emesis. When these two subjects were excluded from the analysis of delayed emesis, the difference between the two groups remained statistically significant (p < 0.001).
The commonest adverse effect was headache and constipation. Two patients reported transient fever which was probably not related to treatment (Table 3 ). The great majority of patients were treated on an outpatient basis, and there was no hospitalisation or prolongation of hospital stay as a result of treatment. 
Discussion
The present study confirms that granisetron with dexamethasone is an effective antiemetic combination for patients receiving moderately emetogenic cytotoxic chemotherapy. There was complete control of acute nausea and vomiting in 73% of patients in the first 24 hours after chemotherapy. With the addition of oral dexamethasone, there was complete or major control of delayed emesis in 87% of patients over the next 6 days.
Although usually seen in patients treated with cisplatin, nausea and vomiting can occur up to several days after cyclophosphamide-based moderately emetogenic chemotherapy regimens. This delay is probably due to the time required for hepatic metabolism of cyclophosphamide to its active metabolite phospharamide mustard [13, 14] . With cyclophosphamide alone, nausea and vomiting begin to develop 6 to 12 hours after administration, peak at about 12 hours and continue for several days. In one study, up to 25% and 15% of patients still complained of nausea on day 4 and day 5, respectively, and 55% of patients who vomited during the study period had only delayed vomiting [15] . These chemotherapies are often given on an outpatient basis at most oncology centres and patients are discharged to return home within minutes after treatment. Intractable nausea and vomiting, if they occur at home, can be a significant problem and seriously affect patients' confidence and compliance [16, 17] .
Dexamethasone was first employed successfully by Rich et al. [18] with phenothiazine as antiemetics. Its efficacy was later confirmed by comparing its combination with prochlorperazine versus placebo with prochlorperazine [19] , and with hydroxizine plus prochlorperazine versus these two drugs without steroids [20] . As single-agent, dexamethasone is superior to placebo [21] , prochlorperazine [22] , and even metoclopramide used at high dosage [23] . Compared with oral ondansetron, patients given oral dexamethasone had better control of delayed nausea when receiving non-cisplatin chemotherapy [24] . When added to ondansetron, it has been shown to prevent delayed emesis in patients receiving cisplatin [25] [26] [27] . In our study the antiemetic activity of granisetron was extended over the next few days with the addition of oral dexamethasone, and a larger number of patients were able to remain emesisfree.
More than 70% of patients reported self-medicating with oral antiemetics at home, and up to one-third of patients did so even on the 5 th day after chemotherapy [15] . Unlike many other antiemetics which cause drowsiness and somnolence, patients treated with dexamethasone were able to carry on their daily activity [22] . Side effects associated with short duration of lowdose treatment are negligible. Dyspepsia, often thought to be associated with steroid use, is not common among patients [28] . Although its effect on the overall quality of life and compliance of patients remains un-known, our study shows that it is a safe and effective method for the control of delayed emesis. Confirmation of our data will need a larger-scale study. Whether shorter duration of dexamethasone e.g., 3 days, is equally effective, should also be evaluated.
